1. Home
  2. MOB vs ANIX Comparison

MOB vs ANIX Comparison

Compare MOB & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MOB

Mobilicom Limited

HOLD

Current Price

$5.15

Market Cap

84.0M

Sector

Real Estate

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.06

Market Cap

100.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOB
ANIX
Founded
2008
1982
Country
Israel
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.0M
100.7M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MOB
ANIX
Price
$5.15
$3.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$8.67
AVG Volume (30 Days)
90.6K
278.9K
Earning Date
03-23-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$150.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$2.32
52 Week High
$11.01
$5.46

Technical Indicators

Market Signals
Indicator
MOB
ANIX
Relative Strength Index (RSI) 45.29 56.35
Support Level $4.72 $2.90
Resistance Level $6.74 $3.09
Average True Range (ATR) 0.41 0.26
MACD 0.01 0.04
Stochastic Oscillator 34.91 62.43

Price Performance

Historical Comparison
MOB
ANIX

About MOB Mobilicom Limited

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: